Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II study of PTX 252 in patients with acute myeloid leukemia

Next Previous
Trial Profile

A phase II study of PTX 252 in patients with acute myeloid leukemia

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PTX 252 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Pleco Therapeutics

Most Recent Events

  • 26 Mar 2025 According to a Pleco Therapeutics media release, the pre-IND meeting held recently, provided an opportunity to discuss Investigational New Drug (IND) development plan and receive FDA guidance on clinical study requirements for PTX-252. The meeting addressed the continued development of PTX-252, an intravenous (IV) formulation designed to treat patients with Acute Myeloid Leukaemia (AML). Also, company is co-developing PTX-252 with Belgian based specialty pharma company Hyloris Pharmaceuticals.
  • 07 Sep 2023 New trial record
  • 05 Sep 2023 According to a Pleco Therapeutics media release, the company expects to start the clinical phase II study for PTX-252 in AML in 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top